CN105616702A - Medicine for preventing and treating chronic glomerulonephritis - Google Patents
Medicine for preventing and treating chronic glomerulonephritis Download PDFInfo
- Publication number
- CN105616702A CN105616702A CN201610078939.9A CN201610078939A CN105616702A CN 105616702 A CN105616702 A CN 105616702A CN 201610078939 A CN201610078939 A CN 201610078939A CN 105616702 A CN105616702 A CN 105616702A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- chronic glomerulonephritis
- polyporus
- paeoniae rubra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to medicine for preventing and treating chronic glomerulonephritis. The medicine is prepared from, by weight, 15-35 parts of semen plantaginis, 10-30 parts of coxtex moutan, 10-25 parts of caulis spatholobi, 10-25 parts of rhizoma corydalis, 10-30 parts of polyporus umbellatus, 10-25 parts of radix paeoniae rubra, 5-20 parts of Lysimachia christinae Hance, 5-25 parts of gentiana macrophylla, 10-20 parts of fructus rubi, 10-35 parts of houttuynia cordata, 5-25 parts of carthamus tinctorious and 5-20 parts of fructus lycii. The medicine has effects of promoting urination and qi circulation, promoting blood circulation to remove blood stasis, clearing away heat and toxic material and dispelling wind and eliminating dampness and is evident in preventing and treating effects on the chronic glomerulonephritis and free of toxic and side effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, in particular to the medicine of a kind of prevention and treatment chronic glomerulonephritis.
Background technology
Chronic glomerulonephritis is called for short chronic nephritis, clinical characters is course of disease length, slower development, symptom can gently can weigh, there is asymptomatic urine examination anomalistic period more, then edema in various degree, albuminuria, microscopic hematuria occur, can accompanied with hypertension and (or) azotemia, and the renal function injury that Progressive symmetric erythrokeratodermia increases the weight of. The end stagerenaldisease in chronic kidney disease and course of disease stage at end thereof sickness rate in the world raises year by year, with its case fatality rate, treatment cost height, the feature serious harm human healths such as awareness, cure rate are low, poor prognosis, the sickness rate of chronic nephritis is more and more higher in recent years, increasingly rejuvenation, brings huge financial burden to country and individual, and property nephritis is clinical department of internal medicine refractory disease, eventually developing into renal failure, patient has to accept renal replacement therapies.
Albuminuria is one of the modal clinical manifestation of CGN and the index that can detect the earliest; substantial amounts of Clinical and experimental study finds; urine protein itself has nephrotoxicity; it is by a kind of lasting, the independent degradation factors of renal failure; it it is a kind of important symbol of CGN prognosis mala; so reducing and eliminating albuminuria, it is one of important measures protecting renal function. Treatment chronic nephritis does not mainly recur, and its traditional treatment measure generally adopts general treatment and hormone, immunosuppressant treatment etc. Due to repeatability and strong side effect, increasing people repels hormone, immunosuppressant class medicine, it is necessary to new chronic nephritis Therapeutic Method.
Chronic nephritis belongs to the categories such as the traditional Chinese medical science " edema ", " asthenia ", " lumbago ", " hematuria " according to clinical manifestation. Ancient Chinese medicine doctor all think edema and hematuria the cause of disease and diseases caused by exogenous pathogenic factor six because of in " ailment said due to cold or exposure ", " water wets " is relevant. " edema due to wind pathogen " that "Nei Jing" proposes is similar with the kidney disease caused by external ailment said due to cold or exposure, " Plain Questions hydro-thermal cave opinion " points out that the reason causing edema due to wind pathogen is: " brave and labor very; then kidney sweating, exposure to the wind after sweating involving in the kidney, interior must not enter internal organs; outward must not more in skin; visitor is in Xuan Fu, row, in flesh side, passes as swollen; basis in kidney, name says edema due to wind pathogen ". " General Treatise on the Cause and Symptoms of Diseases " is said: " ailment said due to cold or exposure enters few the moon then hematuria ". Visible ailment said due to cold or exposure, water wet the importance in morbidity. Wet the lying hidden and undeveloped of water is not changed, with the passing of time heat-transformation, and heat is closed with wet, just becomes damp and hot card, and thus, water is wet is wet thermogenetic basis. Blood stasis is also lead edematigenous key factor, as described in " Medical Treasures of the Golden Chamber ": " menstruation disorder is then water ", and " treatise on blood trouble " is pointed out: " blood and water not from ", " multiple abscess due to blood stasis also floods swollen person, is the blood card that becomes water ". Chronic nephritis is once occur thus, namely creates damp and hot and blood stasis, and namely both be pathological product, is again paathogenic factor, and influences each other, and blood stasis increases the weight of damp and hot, damp and hot obstruction blood, causes state of an illness sustainable development, and delay difficulty is more.
Summary of the invention
The present invention provides a kind of prevention and the medicine for the treatment of chronic glomerulonephritis, and this medicine has effect of diuretic circulation of qi promoting, blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, expelling wind and removing dampness, is used for preventing and treating chronic glomerulonephritis, has no side effect, and effect is notable.
Concrete, one aspect of the present invention provides a kind of prevention and the medicine for the treatment of chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 15-35 part, Cortex Moutan 10-30 part, Caulis Spatholobi 10-25 part, Rhizoma Corydalis 10-25 part, Polyporus 10-30 part, Radix Paeoniae Rubra 10-25 part, Herba Lysimachiae 5-20 part, Radix Gentianae Macrophyllae 5-25 part, Fructus Rubi 10-20 part, Herba Houttuyniae 10-35 part, Flos Carthami 5-25 part, Fructus Lycii 5-20 part.
In one specific embodiment of the present invention, described a kind of prevention and the medicine for the treatment of chronic glomerulonephritis are made up of the crude drug of following weight portion: Semen Plantaginis 20-35 part, Cortex Moutan 10-25 part, Caulis Spatholobi 15-25 part, Rhizoma Corydalis 10-20 part, Polyporus 10-25 part, Radix Paeoniae Rubra 15-25 part, Herba Lysimachiae 15-20 part, Radix Gentianae Macrophyllae 10-25 part, Fructus Rubi 10-15 part, Herba Houttuyniae 10-20 part, Flos Carthami 5-20 part, Fructus Lycii 15-20 part.
In one specific embodiment of the present invention, described a kind of prevention and the medicine for the treatment of chronic glomerulonephritis are made up of the crude drug of following weight portion: Semen Plantaginis 15-25 part, Cortex Moutan 20-30 part, Caulis Spatholobi 15-25 part, Rhizoma Corydalis 10-20 part, Polyporus 20-30 part, Radix Paeoniae Rubra 15-25 part, Herba Lysimachiae 5-15 part, Radix Gentianae Macrophyllae 10-25 part, Fructus Rubi 15-20 part, Herba Houttuyniae 20-35 part, Flos Carthami 15-25 part, Fructus Lycii 5-15 part.
In one specific embodiment of the present invention, described a kind of prevention and the medicine for the treatment of chronic glomerulonephritis are made up of the crude drug of following weight portion: Semen Plantaginis 27 parts, Cortex Moutan 23 parts, Caulis Spatholobi 16 parts, Rhizoma Corydalis 19 parts, Polyporus 28 parts, Radix Paeoniae Rubra 14 parts, Herba Lysimachiae 14 parts, Radix Gentianae Macrophyllae 20 parts, Fructus Rubi 17 parts, Herba Houttuyniae 32 parts, 21 parts of Flos Carthami, Fructus Lycii 15 parts.
In one specific embodiment of the present invention, described a kind of prevention and the medicine for the treatment of chronic glomerulonephritis are made up of the crude drug of following weight portion: Semen Plantaginis 30 parts, Cortex Moutan 25 parts, Caulis Spatholobi 15 parts, Rhizoma Corydalis 20 parts, Polyporus 15 parts, Radix Paeoniae Rubra 20 parts, Herba Lysimachiae 10 parts, Radix Gentianae Macrophyllae 20 parts, Fructus Rubi 15 parts, Herba Houttuyniae 30 parts, 20 parts of Flos Carthami, Fructus Lycii 15 parts.
In one specific embodiment of the present invention, described a kind of prevention and the medicine for the treatment of chronic glomerulonephritis are made up of the crude drug of following weight portion: Semen Plantaginis 20 parts, Cortex Moutan 15 parts, Caulis Spatholobi 20 parts, Rhizoma Corydalis 15 parts, Polyporus 25 parts, Radix Paeoniae Rubra 15 parts, Herba Lysimachiae 18 parts, Radix Gentianae Macrophyllae 23 parts, Fructus Rubi 12 parts, Herba Houttuyniae 26 parts, 17 parts of Flos Carthami, Fructus Lycii 13 parts.
The preparation method that another aspect of the present invention provides the medicine of a kind of prevention and treatment chronic glomerulonephritis, it is characterised in that the preparation method of this pharmaceutical composition comprises the following steps:
(1) Cortex Moutan, Caulis Spatholobi, Polyporus, Herba Lysimachiae, Herba Houttuyniae, Flos Carthami add soak by water 2-3 time accounting for gross weight 8-15 times amount, each 1.5-2 hour, collecting decoction, add the aqueous solution that step (1) is obtained, filtering, filtrate is concentrated into the extractum that relative density is 1.15-1.25 (I) when 80 DEG C;
(2) by Semen Plantaginis, Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Gentianae Macrophyllae, Fructus Rubi, Fructus Lycii add account for gross weight 8-15 times amount 85% alcoholic solution in extract 2-3 time, each 2-3 hour, filter, merging filtrate, place overnight, reclaim ethanol, the extractum that relative density is 1.15-1.25 (II) when concentrating the filtrate to 60 DEG C;
(3) in step (1), the mixing of (2) gained extractum, dry, stir, to obtain final product.
In a specific embodiment of the present invention, step (1) wherein adds the soak by water 3 times accounting for gross weight 10 times amount, each 1.5 hours; Step (2) accounts for gross weight 10 times amount 85% alcoholic solution in extract 2 times, each 3 hours.
The medicine of prevention of the present invention and treatment chronic glomerulonephritis, it is also possible to prepare according to the conventional method of the field of Chinese medicines, including soak by water, each crude drug is ground into powder etc. The conventional method that can adopt Chinese medicine preparation prepares into any traditional oral preparation. Described oral formulations is capsule, pill, powder, tablet, granule, decoction, soft capsule.
The pharmaceutical composition of the present invention, based on the dialectical prescription of tcm theory, this medicine has effect of diuretic circulation of qi promoting, blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, expelling wind and removing dampness, is used for preventing and treating chronic glomerulonephritis, has no side effect, and effect is notable.
Detailed description of the invention
Embodiment 1:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 27g, Cortex Moutan 23g, Caulis Spatholobi 16g, Rhizoma Corydalis 19g, Polyporus 28g, Radix Paeoniae Rubra 14g, Herba Lysimachiae 14g, Radix Gentianae Macrophyllae 20g, Fructus Rubi 17g, Herba Houttuyniae 32g, Flos Carthami 21g, Fructus Lycii 15g;
Each crude drug is dried at 45 DEG C, is cooled to room temperature, grind into fine powder state, and mix homogeneously, loads snap fit capsule, to obtain final product.
Embodiment 2:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 27g, Cortex Moutan 23g, Caulis Spatholobi 16g, Rhizoma Corydalis 19g, Polyporus 28g, Radix Paeoniae Rubra 14g, Herba Lysimachiae 14g, Radix Gentianae Macrophyllae 20g, Fructus Rubi 17g, Herba Houttuyniae 32g, Flos Carthami 21g, Fructus Lycii 15g;
Weigh said medicine by formula ratio, be added to the water, boil, slow fire boiling 30 minutes, filter, filtering residue adds water, slow fire boiling 30 minutes, merge twice medicinal liquid, to obtain final product.
Embodiment 3:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 27g, Cortex Moutan 23g, Caulis Spatholobi 16g, Rhizoma Corydalis 19g, Polyporus 28g, Radix Paeoniae Rubra 14g, Herba Lysimachiae 14g, Radix Gentianae Macrophyllae 20g, Fructus Rubi 17g, Herba Houttuyniae 32g, Flos Carthami 21g, Fructus Lycii 15g;
Preparation method comprises the following steps:
(1) Cortex Moutan, Caulis Spatholobi, Polyporus, Herba Lysimachiae, Herba Houttuyniae, Flos Carthami add the soak by water 3 times accounting for gross weight 10 times amount, each 2 hours, collecting decoction, add the aqueous solution that step (1) is obtained, filtering, filtrate is concentrated into the extractum that relative density is 1.15-1.25 (I) when 80 DEG C;
(2) by Semen Plantaginis, Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Gentianae Macrophyllae, Fructus Rubi, Fructus Lycii add account for gross weight 10 times amount 85% alcoholic solution in extract 3 times, each 2 hours, filter, merging filtrate, place overnight, reclaim ethanol, the extractum that relative density is 1.15-1.25 (II) when concentrating the filtrate to 60 DEG C;
(3) in step (1), the mixing of (2) gained extractum, dry, stir, load capsule and get final product.
Embodiment 4:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 30g, Cortex Moutan 25g, Caulis Spatholobi 15g, Rhizoma Corydalis 20g, Polyporus 15g, Radix Paeoniae Rubra 20g, Herba Lysimachiae 10g, Radix Gentianae Macrophyllae 20g, Fructus Rubi 15g, Herba Houttuyniae 30g, Flos Carthami 20g, Fructus Lycii 15g;
Weigh said medicine by formula ratio, be added to the water, boil, slow fire boiling 30 minutes, filter, filtering residue adds water, slow fire boiling 30 minutes, merge twice medicinal liquid, to obtain final product.
Embodiment 5:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 20g, Cortex Moutan 15g, Caulis Spatholobi 20g, Rhizoma Corydalis 15g, Polyporus 25g, Radix Paeoniae Rubra 15g, Herba Lysimachiae 18g, Radix Gentianae Macrophyllae 23g, Fructus Rubi 12g, Herba Houttuyniae 26g, Flos Carthami 17g, Fructus Lycii 13g;
Weigh said medicine by formula ratio, be added to the water, boil, slow fire boiling 30 minutes, filter, filtering residue adds water, slow fire boiling 30 minutes, merge twice medicinal liquid, to obtain final product.
Comparative example 1:
The medicine of a kind of prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 27g, Cortex Moutan 23g, Caulis Spatholobi 16g, Rhizoma Corydalis 19g, Polyporus 28g, Radix Paeoniae Rubra 14g, Herba Lysimachiae 14g, Radix Gentianae Macrophyllae 20g, Fructus Rubi 17g, Herba Houttuyniae 32g;
Each crude drug is dried at 45 DEG C, is cooled to room temperature, grind into fine powder state, and mix homogeneously, loads snap fit capsule, to obtain final product.
Embodiment 6: medicine of the present invention is to the preventive and therapeutic effect to rat Passive-Heymann Nephritis model
Passive-type Heymarm nephritis is the classical model of research mankind's membranous nephropathy, with High-grade Proteinuria for marked feature [Chinese Journal of Nephrology .1999.15 (3): 158]. Therefore, present invention Heymann Nephritis Model studies the medicine of the present invention preventive and therapeutic effect to nephritis.
1, experimental animal
Wistar rat, male, body weight: 175��200 grams
2, test method
2.1 prepare anti-FX1A serum
1) FX1A antigen is prepared
Normal male Wistar rat, sterilization skin after etherization, cut off splanchnocoel, with aseptic cold saline lavation kidney, it is then peeled off renal cortex to weigh, appropriate normal saline is added after cortex is fully ground into homogenate, filter with 80 orders, 100 orders and 220 eye mesh screens successively, collect last filtrate, filtrate is centrifuged with 1600r/min20min, take supernatant, repeated centrifugation once, takes supernatant, then with 10000r/min30min centrifugal after abandon supernatant, being washed 3 times by precipitate distilled water, gained precipitate is FXA1A antigen.
2) anti-FX1A serum is prepared
After fully emulsified to the FXA1A antigen of above-mentioned preparation and equal-volume Freund's complete adjuvant, interval takes serum through subcutaneous inoculation large ear rabbit after being total to immune 6 times in 2 weeks. Measure titer by immunity directional diffusion and indirect immunofluorescence, respectively reach 1: 32 and 1: 2000 for qualified. Carotid artery takes blood, separates serum, and it is anti-FX1A serum, and-20 DEG C standby, uses front inactivation.
2.2, the foundation of Passive-Heymann Nephritis model model and animal packet
Extracting male Wistar rat 75, their 24h urine protein is respectively less than 10mg. Stochastic averagina is divided into 5 groups: positive controls, medicine group of the present invention, comparative example 1 medicine group, model control group and blank group. The disposable tail vein injection saline 5ml/kg of blank group; All the other are respectively organized the anti-FX1A serum 5ml/kg of the disposable tail vein injection of rat and carry out modeling, per os gastric infusion every day (dosage calculates respectively) was played with every kg body weight the same day in modeling, totally 4 weeks, dosage respectively positive controls (dexamethasone, 0.1mg/kg/d); Medicine group (30g/kg/d) of the present invention; Comparative example 1 medicine group (30mg/kg/d); Sodium carboxymethyl cellulose (CMCNa) the suspension 5mg/kg/d of model group comparison and blank group every rat oral perfusion 0.5% every day. (capsule 's content and dexamethasone prepared by the capsule 's content of the embodiment of the present invention 1 preparation, comparative example 1 make respective concentration by sodium carboxymethyl cellulose (CMCNa) mixture of 0.5% respectively)
2.3, observation index
Urine protein quantitation adopts BCA (bicinchoninincacid) method, and 5 groups all start to be respectively put in metabolic cage in modeling the 2nd and the 4th week weekend, collects 24h urine. Measurement data represents with mean �� standard deviation (x �� SD), and each group compares with model group respectively, adopts bilateral two sample t-test to carry out statistical analysis.
The impact on rat urine protein content of table 1 medicine of the present invention
| Group | 14th day urine albumen amount (mg/24h) | 28th day urine albumen amount (mg/24h) |
| Blank group | 4.6��1.2** | 4.8��1.6** |
| Model control group | 42.5��23.4 | 47.2��25.8 |
| Positive controls | 12.5��4.2** | 15.8��4.7** |
| Medicine group of the present invention | 13.2��4.3** | 16.8��3.6** |
| Comparative example 1 medicine group | 18.5��4.7** | 20.7��4.5** |
Compare with model group:**P < 0.01
From table 1, medicine group urine albumen amount of the present invention is significantly lower than model group (P < 0.05), close to positive controls, illustrate that Passive-Heymann Nephritis model is had significant curative effect by medicine of the present invention, and each component of Chinese medicine of the present invention is worked in coordination with mutually, omitting two of which component effect can decline.
Embodiment 7 clinical trial
For confirming the curative effect of Drug therapy chronic nephritis of the present invention, the Chinese medicine of embodiment 2 preparation is adopted to carry out following clinical and experimental study
1, physical data:
100 examples meeting this patient of diagnostic criteria, is divided into treatment group 50 example and matched group 50 example according to randomization, two groups of physical data, through statistical procedures no significant difference (P > 0.05), have comparability. The primary glomerulopathy diagnostic criteria that chronic nephritis diagnostic criteria is formulated with reference to the nephropathy special interest group discussion of in June, 1992 " CHINESE JOURNAL OF INTERNAL MEDICINE " editorial board. All meeting chronic nephritis diagnostic criteria, the age, normal renal function person all included the object of observation in 15-65 year. Get rid of pregnant and lactating women, merge disease and the allergic constitution persons such as severe cardiac, brain, liver and hemopoietic system.
2, Therapeutic Method
Matched group: adopt prednisone 1mg/kg d, every day is oral once, is used in conjunction 8 weeks, decrement gradually, weekly decrement 10% to maintenance dose. There is the infected, control to infect, but avoid using renal damage medicine; There is hypertension patient, select ACEI preparation or calcium antagonist and high quality protein diet etc.
Treatment group: add the Chinese medicine of the embodiment of the present invention 2 on matched group basis, potion, divided and took for three times every day.
Two groups all with two months for a course for the treatment of. Twenty-four-hour urine protein quantification, renal function and main clinic symptoms situation of change before and after main detection two groups treatment.
3, curative effect judging standard
The curative effect determinate standard that criterion of therapeutical effect is formulated with reference to the nephropathy special interest group discussion of " CHINESE JOURNAL OF INTERNAL MEDICINE " editorial board.
Complete incidence graph: clinical symptom disappearance, urine protein is turned out cloudy, urine protein quantitation < 0.28g/d, normal renal function;
Notable alleviate: clinical symptom disappearance or alleviate, urine protein quantitation 0.2-1.0g/d, or quantitatively reduce >=50%, stable renal function;
Partial rcsponse: clinical symptom relief, urine protein < 3g/d or > 3g/d, but quantitatively reduce >=50%, stable renal function;
Invalid: symptom is without improving or increasing the weight of, and urine protein does not reduce, and serum creatinine increases >=1 times.
4, result
Treat after two months:
Treatment group: complete incidence graph 28 example, notable alleviation 13 examples, partial rcsponse 7 example, invalid 2 examples;
Matched group: complete incidence graph 12 example, notable alleviation 12 examples, partial rcsponse 16 example, invalid 10 examples.
5, before and after two groups of treatments, twenty-four-hour urine protein quantification compares (see table 2)
The impact on urine albumen amount of table 2 medicine of the present invention
With this group before treatment*P < 0.05
Being shown by the data of table 2, medicine of the present invention can substantially reduce Urinary protein content.
Claims (8)
1. a medicine for prevention and treatment chronic glomerulonephritis, is made up of the crude drug of following weight portion: Semen Plantaginis 15-35 part, Cortex Moutan 10-30 part, Caulis Spatholobi 10-25 part, Rhizoma Corydalis 10-25 part, Polyporus 10-30 part, Radix Paeoniae Rubra 10-25 part, Herba Lysimachiae 5-20 part, Radix Gentianae Macrophyllae 5-25 part, Fructus Rubi 10-20 part, Herba Houttuyniae 10-35 part, Flos Carthami 5-25 part, Fructus Lycii 5-20 part.
2. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1, is made up of the crude drug of following weight portion: Semen Plantaginis 20-35 part, Cortex Moutan 10-25 part, Caulis Spatholobi 15-25 part, Rhizoma Corydalis 10-20 part, Polyporus 10-25 part, Radix Paeoniae Rubra 15-25 part, Herba Lysimachiae 15-20 part, Radix Gentianae Macrophyllae 10-25 part, Fructus Rubi 10-15 part, Herba Houttuyniae 10-20 part, Flos Carthami 5-20 part, Fructus Lycii 15-20 part.
3. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1, is made up of the crude drug of following weight portion: Semen Plantaginis 15-25 part, Cortex Moutan 20-30 part, Caulis Spatholobi 15-25 part, Rhizoma Corydalis 10-20 part, Polyporus 20-30 part, Radix Paeoniae Rubra 15-25 part, Herba Lysimachiae 5-15 part, Radix Gentianae Macrophyllae 10-25 part, Fructus Rubi 15-20 part, Herba Houttuyniae 20-35 part, Flos Carthami 15-25 part, Fructus Lycii 5-15 part.
4. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1, is made up of the crude drug of following weight portion: Semen Plantaginis 27 parts, Cortex Moutan 23 parts, Caulis Spatholobi 16 parts, Rhizoma Corydalis 19 parts, Polyporus 28 parts, Radix Paeoniae Rubra 14 parts, Herba Lysimachiae 14 parts, Radix Gentianae Macrophyllae 20 parts, Fructus Rubi 17 parts, Herba Houttuyniae 32 parts, 21 parts of Flos Carthami, Fructus Lycii 15 parts.
5. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1, is made up of the crude drug of following weight portion: Semen Plantaginis 30 parts, Cortex Moutan 25 parts, Caulis Spatholobi 15 parts, Rhizoma Corydalis 20 parts, Polyporus 15 parts, Radix Paeoniae Rubra 20 parts, Herba Lysimachiae 10 parts, Radix Gentianae Macrophyllae 20 parts, Fructus Rubi 15 parts, Herba Houttuyniae 30 parts, 20 parts of Flos Carthami, Fructus Lycii 15 parts.
6. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1, is made up of the crude drug of following weight portion: Semen Plantaginis 20 parts, Cortex Moutan 15 parts, Caulis Spatholobi 20 parts, Rhizoma Corydalis 15 parts, Polyporus 25 parts, Radix Paeoniae Rubra 15 parts, Herba Lysimachiae 18 parts, Radix Gentianae Macrophyllae 23 parts, Fructus Rubi 12 parts, Herba Houttuyniae 26 parts, 17 parts of Flos Carthami, Fructus Lycii 13 parts.
7. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 1-6, it is characterised in that adopt the conventional method of Chinese medicine preparation to prepare into any traditional oral preparation.
8. a kind of medicine prevented and treat chronic glomerulonephritis described in claim 7, it is characterised in that described oral formulations is capsule, pill, powder, tablet, granule, decoction, soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610078939.9A CN105616702A (en) | 2016-02-04 | 2016-02-04 | Medicine for preventing and treating chronic glomerulonephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610078939.9A CN105616702A (en) | 2016-02-04 | 2016-02-04 | Medicine for preventing and treating chronic glomerulonephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105616702A true CN105616702A (en) | 2016-06-01 |
Family
ID=56032313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610078939.9A Pending CN105616702A (en) | 2016-02-04 | 2016-02-04 | Medicine for preventing and treating chronic glomerulonephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105616702A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115477A (en) * | 2017-06-13 | 2017-09-01 | 青岛市中心医院 | A kind of Chinese medicine composition for preventing and treating chronic nephritis |
| CN107213262A (en) * | 2017-06-13 | 2017-09-29 | 青岛市中心医院 | A kind of medicine for preventing and treating CGN |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961706A (en) * | 2012-11-20 | 2013-03-13 | 西安泰科迈医药科技有限公司 | Pure traditional Chinese medicine compound preparation for treating chronic glomerulonephritis and preparation method thereof |
| CN203291231U (en) * | 2012-10-12 | 2013-11-20 | 潍坊复能肾病研究院 | Preparation system for traditional Chinese medicine composition liquid medicine through targeted transferring in renal region |
| CN103656299A (en) * | 2013-12-16 | 2014-03-26 | 青岛百瑞吉生物工程有限公司 | Chinese herbal preparation for treating chronic glomerulonephritis |
| CN103768268A (en) * | 2014-01-15 | 2014-05-07 | 赵文革 | Traditional Chinese medicine for treating primary glomerulonephritis |
| CN103933387A (en) * | 2014-04-08 | 2014-07-23 | 李太凤 | Traditional Chinese medicine preparation for treating chronic glomerulonephritis |
| CN104258206A (en) * | 2014-09-15 | 2015-01-07 | 伏淼 | Traditional Chinese medicine preparation for treating acute glomerulonephritis |
| CN104667020A (en) * | 2015-03-20 | 2015-06-03 | 孙号 | Pharmaceutical composition for treating anaphylactoid purpura and preparation method of pharmaceutical composition |
| CN104689216A (en) * | 2015-03-30 | 2015-06-10 | 刘军芳 | Medicine for treating chronic nephritis |
| CN105194337A (en) * | 2015-11-05 | 2015-12-30 | 孙绪连 | Medicine for treating idiopathic tubulointerstitial nephritis |
-
2016
- 2016-02-04 CN CN201610078939.9A patent/CN105616702A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN203291231U (en) * | 2012-10-12 | 2013-11-20 | 潍坊复能肾病研究院 | Preparation system for traditional Chinese medicine composition liquid medicine through targeted transferring in renal region |
| CN102961706A (en) * | 2012-11-20 | 2013-03-13 | 西安泰科迈医药科技有限公司 | Pure traditional Chinese medicine compound preparation for treating chronic glomerulonephritis and preparation method thereof |
| CN103656299A (en) * | 2013-12-16 | 2014-03-26 | 青岛百瑞吉生物工程有限公司 | Chinese herbal preparation for treating chronic glomerulonephritis |
| CN103768268A (en) * | 2014-01-15 | 2014-05-07 | 赵文革 | Traditional Chinese medicine for treating primary glomerulonephritis |
| CN103933387A (en) * | 2014-04-08 | 2014-07-23 | 李太凤 | Traditional Chinese medicine preparation for treating chronic glomerulonephritis |
| CN104258206A (en) * | 2014-09-15 | 2015-01-07 | 伏淼 | Traditional Chinese medicine preparation for treating acute glomerulonephritis |
| CN104667020A (en) * | 2015-03-20 | 2015-06-03 | 孙号 | Pharmaceutical composition for treating anaphylactoid purpura and preparation method of pharmaceutical composition |
| CN104689216A (en) * | 2015-03-30 | 2015-06-10 | 刘军芳 | Medicine for treating chronic nephritis |
| CN105194337A (en) * | 2015-11-05 | 2015-12-30 | 孙绪连 | Medicine for treating idiopathic tubulointerstitial nephritis |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107115477A (en) * | 2017-06-13 | 2017-09-01 | 青岛市中心医院 | A kind of Chinese medicine composition for preventing and treating chronic nephritis |
| CN107213262A (en) * | 2017-06-13 | 2017-09-29 | 青岛市中心医院 | A kind of medicine for preventing and treating CGN |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105616702A (en) | Medicine for preventing and treating chronic glomerulonephritis | |
| CN103656538B (en) | Be used for the treatment of the Chinese medicine preparation of invisible glomerulonephritis hematuria | |
| CN105561004A (en) | Traditional Chinese medicine composition for preventing and treating chronic nephritis | |
| CN101810826B (en) | Chinese medicament for treating liver cancer | |
| CN105056128B (en) | A kind of Chinese medicine composition and preparation method and application for treating atrophic gastritis and intestines | |
| CN106074810A (en) | A kind of three wonderful capsules and preparation method thereof | |
| CN108743887A (en) | Treat the Chinese medicine composition and preparation method thereof of liver fibrosis and hepatic sclerosis | |
| CN110064016B (en) | Traditional Chinese medicine composition for regulating immune state of chronic kidney disease and preparation method thereof | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN1781538A (en) | Chinese medicine preparation for treating mephritis and nephrosis syndrome | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN103316214B (en) | Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
| CN107213262A (en) | A kind of medicine for preventing and treating CGN | |
| CN107115477A (en) | A kind of Chinese medicine composition for preventing and treating chronic nephritis | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN103520538B (en) | A kind ofly treat the pharmaceutical composition that diabetes cause kidney damage | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN115040617B (en) | Traditional Chinese medicine composition for treating dampness-eliminating and inter-junction type primary sicca syndrome as well as preparation method and application thereof | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN106880828A (en) | A kind of Chinese medicine composition for treating spleen kidney qi deficiency of yang type primary nephrotic syndrome | |
| CN105456947A (en) | Pharmaceutical composition for treating avascular necrosis of femoral head and application thereof | |
| CN116474036A (en) | Traditional Chinese medicine composition and application thereof | |
| CN104758710A (en) | External application traditional Chinese medicine used for treating allergic rhinitis | |
| CN115317550A (en) | Traditional Chinese medicine composition for treating chronic prostatitis/chronic pelvic pain syndrome and preparation method and application thereof | |
| CN103877421B (en) | A kind of medicine treating hematuria in chidren and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160601 |
|
| RJ01 | Rejection of invention patent application after publication |